

**Collaborative Consult: Cases, Patient Reflection, and Discussions:  
What's New in Pediatric Atopic Dermatitis**

**References**

**Tweet 4**

Paller A, Antila M, Marcoux D, et al. *J Allergy Clin Immunol*. 2022;149(2S):AB8

**Tweet 6**

Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. *Ann Allergy Asthma Immunol*. 2018;120(1):10-22.e12. doi:10.1016/j.anai.2017.10.039

Chiricozzi A, Comberiati P, D'Auria E, Zucotti G, Peroni DG. Topical corticosteroids for pediatric atopic dermatitis: Thoughtful tips for practice. *Pharmacol Res*. 2020;158:104878.

Eichenfield LF, DiBonaventura, Xenakis J, et al. Costs and treatment patterns among patients with atopic dermatitis using advanced therapies in the united states: analysis of a retrospective claims database. *Dermatol Ther (Heidelb)*. 2020;10(4):791-806. doi:10.1007/s13555-020-00413-8

He A, Feldman SR, Fleischer AB. An assessment of the use of antihistamines in the management of atopic dermatitis. *J Am Acad Dermatol*. 2018;79(1):92-96. doi:10.1016/j.jaad.2017.12.077

Paller AS, Siegfried EC, Vekeman F, et al. Treatment patterns of pediatric patients with atopic dermatitis: A claims data analysis. *J Am Acad Dermatol*. 2020;82(3):651-660. doi:10.1016/j.jaad.2019.07.105

Sibbald C, Drucker AM. Patient burden of atopic dermatitis. *Dermatol Clin*. 2017;35(3):303-316. doi:10.1016/j.det.2017.02.004

Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. *Lancet*. 2016;387(10013):40-52. doi:10.1016/S0140-6736(15)00388-8

Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. *J Dermatol*. 2018;45(2):150-157. doi:10.1111/1346-8138.14116

**Tweet 8**

Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. *J Allergy Clin Immunol*. 2012;130(6):1344-1354. doi:10.1016/j.jaci.2012.07.012

Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. *J Allergy Clin Immunol*. 2014;134(4):769-779. doi:10.1016/j.jaci.2014.08.008

Munera-Campos M, Carrascosa JM. Innovation in atopic dermatitis: from pathogenesis to treatment. *Acta Demosifiliogr (Engl Ed)*. 2020;111(3):205-221. doi:10.1016/j.ad.2019.11.002

### **Tweet 9**

Kim BS, Howell DM, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. *J Allergy Clin Immunol*. 2020;145(2):572-582. doi:10.1016/j.jaci.2019.08.042

Silverberg JI, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. *J Allergy Clin Immunol*. 2022;149(3):977-987.e14. doi:10.1016/j.jaci.2021.07.036.

Simpson EL, Bieber T, Gutmann-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. *N Engl J Med*. 2016 Dec 15;375(24):2335-2348. doi:10.1056/NEJMoa1610020

### **Tweet 10**

Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis. *JAMA Dermatol*. 2020;156:44-56. doi:10.1001/jamadermatol.2019.3336

Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. *J Am Acad Dermatol*. 2020;83:1282-1293. doi:10.1016/j.jaad.2020.06.054

Paller AS, et al. Presented at: RAD 2021; December 11-13, 2021.

### **Tweet 11**

BioSpace. Incyte announces first presentation of phase 3 data from the TRuE-AD program of ruxolitinib cream at the revolutionizing atopic dermatitis virtual symposium. April 5, 2020. Accessed July 22, 2022. <https://www.biospace.com/article/releases/incyte-announces-first-presentation-of-phase-3-data-from-the-true-ad-program-of-ruxolitinib-cream-at-the-revolutionizing-atopic-dermatitis-virtual-symposium/>

### **Tweet 12**

Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Werfel T, Zeng J, Huang X, Hu X, Hendrickson BA, Ladizinski B, Chu AD, Silverberg JI. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2021 Jun 5;397(10290):2169-2181.

### **Tweet 13**

Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. *Arch Dermatol*. 2004;140:1513-1519. doi:10.1001/archderm.140.12.1513

Futamura M, Lesehem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. *J Am Acad Dermatol*. 2016;74(2):288-294. doi:10.1016/j.jaad.2015.09.062

Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. *Exp Dermatol*. 2001;10:11-18. doi:10.1034/j.1600-0625.2001.100102.x

Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. *Dermatology*. 1993;186:23-310. doi:10.1159/000247298.

Suh TP, Ramachandran D, Patel V, et al. Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): A practice-friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children. *J Am Acad Dermatol*. 2020;82(5):1187-1194. doi:10.1016/j.jaad.2020.01.023

#### **Tweet 14**

Blaiss M. Paper presented at: American College of Allergy, Asthma & Immunology 2021 Annual Scientific Symposium 2021.

Ervin C, Crawford R, Evans E, et al. Patient and caregiver preferences on treatment attributes for atopic dermatitis. *J Dermatolog Treat*. 2022;33(4):2225-2233. doi:10.1080/09546634.2021.1940810

LeBovidge J, Borok J, Udkoff J, Yosipovitch G, Eichenfield LF. Atopic dermatitis: therapeutic care delivery: therapeutic education, shared decision-making, and access to care. *Semin Cutan Med Surg*. 2017;36(3):131-136. doi:10.12788/j.sder.2017.029

### **Glossary**

AD, atopic dermatitis  
AE, adverse event  
BID, twice a day  
BSA, body surface area  
CS, corticosteroids  
EASI, Eczema Area and Severity Index  
EASI-75, 75% reduction in the Eczema Area and Severity Index  
IGA, Investigator's Global Assessment  
IL, interleukin  
JAK, Janus kinase  
MDC, multidisciplinary care team  
Mod, moderate  
OCS, oral corticosteroids  
POEM, Patient-Oriented Eczema Measure  
PO-SCORAD, Patient-Oriented Scoring Atopic Dermatitis  
Q4W, once every 4 weeks  
SDM, shared decision-making  
STAT, signal transducer and activator of transcription  
TCS, topical corticosteroids  
Th, T-helper cell  
TPE, therapeutic patient education  
UVB, ultraviolet B light  
vIGA, Validated Investigator's Global Assessment  
w/, with  
YOA, years of age